A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions
Glabellar Lines
Interventions
DRUG

AGN-151586

Intramuscular Injection

DRUG

BOTOX

Intramuscular Injection

DRUG

Placebo

Intramuscular Injection

Trial Locations (10)

60069

Advanced Dermatology /ID# 244427, Lincolnshire

60611

DeNova Research /ID# 244421, Chicago

77401

Bellaire Dermatology Associates /ID# 244428, Bellaire

80111

AboutSkin Research, LLC /ID# 244416, Greenwood Village

99202

Premier Clinical Research /ID# 244429, Spokane

92663-3637

The Eye Research Foundation /ID# 244430, Newport Beach

92121-2119

Cosmetic Laser Dermatology /ID# 244425, San Diego

33146-1837

Skin Research Institute LLC /ID# 244424, Coral Gables

33137-3254

Skin and Cancer Associates, LLP /ID# 244415, Miami

46260-2386

Laser and Skin Surgery Center of Indiana /ID# 244423, Indianapolis

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY